Summary
Pfizer Inc. (PFE) filed an 8-K on July 17, 2006, to report a significant reclassification of its financial statements. The company has elected to present its Consumer Healthcare business as a "Discontinued Operation" in its consolidated statements of income for both the full year 2005 and the first quarter of 2006. This change in presentation will allow investors to better distinguish the ongoing performance of Pfizer's core pharmaceutical operations from the results of the divested or soon-to-be-divested Consumer Healthcare segment. The reclassification is effective retroactively for the periods presented, meaning comparative financial results will reflect this change. This move is often a precursor to a sale or spin-off of the business segment being classified as discontinued. Investors should pay close attention to the details within the press release attached as Exhibit 99 for a clearer understanding of the financial impact and Pfizer's strategic rationale behind this presentation change.
Key Highlights
- 1Pfizer is reclassifying its Consumer Healthcare business as a Discontinued Operation.
- 2This reclassification impacts the consolidated statements of income for full year 2005 and Q1 2006.
- 3The change is presented retroactively for comparative purposes.
- 4This accounting treatment typically signals a potential divestiture or spin-off of the business segment.
- 5The press release containing these reclassified statements is filed as Exhibit 99 to the 8-K.
- 6Investors can now better assess the performance of Pfizer's core ongoing operations.